Key Insider Increases Stake Following Recent Public Offering

summarizeSummary

A key insider and affiliated entities purchased over $2 million in Zenas BioPharma common stock, increasing their stake to 4.794% following a recent dilutive public offering.

check_boxKey Events

• Insider Purchases

  Leon O. Moulder, Jr. and Tellus BioVentures, LLC, an entity he controls, collectively purchased 111,000 shares of common stock for approximately $2.04 million in open-market transactions between February 2 and March 31, 2026.

• Increased Beneficial Ownership

  Leon O. Moulder, Jr. now beneficially owns 3,029,921 shares, representing 4.794% of the company's common stock, including shares held directly, through options, and through affiliated entities.

• Post-Offering Confidence

  The purchases by Tellus BioVentures occurred between March 30-31, 2026, immediately following the company's concurrent public offerings of common stock and convertible notes, which were completed on March 31, 2026, and had previously led to a significant stock price drop.

auto_awesomeAnalysis

Leon O. Moulder, Jr., a significant insider, and entities he controls, have collectively purchased over $2 million worth of common stock. These purchases, particularly those by Tellus BioVentures in late March, occurred immediately after the company completed a substantial dilutive public offering and experienced a significant stock price decline. This buying activity signals strong insider confidence in Zenas BioPharma's long-term prospects, despite recent capital raises and market volatility.